<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580255</url>
  </required_header>
  <id_info>
    <org_study_id>200614766</org_study_id>
    <nct_id>NCT00580255</nct_id>
  </id_info>
  <brief_title>Comparison Study of BNP and Thoracic Impedance Measurements on Arrhythmias</brief_title>
  <official_title>Does Elevated Brain Natriuretic Peptide (BNP) Reflect Changes in Thoracic Impedance Levels and Affect Occurrence of Atrial and Ventricular Arrhythmias?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that elevated BNP level correlate with an elevated thoracic&#xD;
      impedance/fluid index as measured separately by CRT-D devices and external impedance&#xD;
      cardiography. Ultimately, it is also hypothesized that both BNP and thoracic impedance/fluid&#xD;
      index measurements are predictive of atrial and ventricular arrhythmias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study:&#xD;
&#xD;
        1. To assess the correlation between elevated brain natriuretic peptide levels and elevated&#xD;
           thoracic impedance/body fluid index as measured by selective biventricular&#xD;
           resynchronization devices and an external impedance cardiography device.&#xD;
&#xD;
        2. Correlate impedance measurements and brain natriuretic levels with occurrence of atrial&#xD;
           and ventricular arrhythmias as assessed by interrogation of biventricular devices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    resources not available&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <condition>Arrhythmias</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Teaspoon of blood drawn for testing of BNP levels.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Potential candidates with criteria for implantable cardiac resynchronization therapy who&#xD;
        have or will undergo implantation of a Medtronic CRT-D device with thoracic impedance&#xD;
        measurement capabilities, will be eligible to enter the study if they meet all of the&#xD;
        inclusion criteria and none of the exclusion criteria. Patients will be enrolled in the&#xD;
        study either at the time of device implantation or if they have already undergone device&#xD;
        implantation will be enrolled at next routine outpatient clinic visit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 18 to 85 years of age.&#xD;
&#xD;
          -  All patients with biventricular implantable cardio-defibrillators(manufacturer:&#xD;
             Medtronic/ model: InSync 7299/7297 or newer).&#xD;
&#xD;
          -  LVEF &lt;35%&#xD;
&#xD;
          -  NYHA III/IV&#xD;
&#xD;
          -  QRS &gt;120 msec&#xD;
&#xD;
          -  Pt willing and able to sign informed consent.&#xD;
&#xD;
          -  Conventional heart failure therapy&#xD;
&#xD;
          -  Clinically stable for six months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age less than 18 years of age&#xD;
&#xD;
          -  age greater than 85 years of age&#xD;
&#xD;
          -  Creatinine &gt; 2.5 mg/dl.&#xD;
&#xD;
          -  End stage liver disease complicated by ascites as determined by electronic medical&#xD;
             record review.&#xD;
&#xD;
          -  women who are pregnant, lactating, or plan to become pregnant during the course of the&#xD;
             study.&#xD;
&#xD;
          -  Patients who are heart transplant candidates with expected transplantation within the&#xD;
             next six months.&#xD;
&#xD;
          -  Life expectancy due to non-cardiac cause less than one year.&#xD;
&#xD;
          -  Anticipated problem with compliance.&#xD;
&#xD;
          -  Critical valvular stenoses/insufficiencies.&#xD;
&#xD;
          -  Morbidly obese patients(&gt;300 lbs.)&#xD;
&#xD;
          -  In patients whom impedance cardiography was not able to be performed because of&#xD;
             inability to place sensors.&#xD;
&#xD;
          -  Planned or known need for revascularization procedures within three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uma Srivatsa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U C Davis Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U C Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ucdmc.ucdavis.edu/ClinicalTrials/</url>
    <description>Clinical Trials at UC Davis Medical Center</description>
  </link>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHF</keyword>
  <keyword>CRT</keyword>
  <keyword>Atrial Arrhythmias</keyword>
  <keyword>Ventricular Arrhythmias</keyword>
  <keyword>BioZ</keyword>
  <keyword>Optivol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

